CollectionsPrevnar
IN THE NEWS

Prevnar

FEATURED ARTICLES
BUSINESS
February 25, 2010 | By Marie McCullough INQUIRER STAFF WRITER
The Food and Drug Administration yesterday approved a new version of the Prevnar childhood vaccine that will provide greater protection against certain serious bacterial infections. Prevnar 13 stimulates the immune system to fight 13 strains of pneumococci - six more than the original top-selling vaccine, introduced in 2000. These bacteria cause potentially deadly meningitis, bloodstream infections, and pneumonia, as well as ear infections. The approval was a champagne-toast moment for New York-based Pfizer Inc., which last year acquired Prevnar's developer Wyeth.
NEWS
January 1, 2012 | Associated Press
WASHINGTON - Federal regulators have approved a vaccine for adults 50 and older to prevent pneumococcal disease, including the most common type of pneumonia. Friday's announcement from the Food and Drug Administration that it had approved Pfizer Inc.'s best-selling Prevnar 13 vaccine for such use was widely anticipated. The approval comes a little more than a month after a panel of federal health experts voted overwhelmingly to recommend Prevnar 13 as a safe and effective vaccine to prevent the bacterial infections in adults.
BUSINESS
April 19, 2009 | By Miriam Hill INQUIRER STAFF WRITER
They are lethal bacteria. They slink into the human body cloaked in any of 91 versions of fuzzy sugar clouds that act as a coat of armor as they assault the immune system. For drug giant Wyeth, the opportunity to prevent these bacteria, known as pneumococci, from causing meningitis in children already rings up $2.7 billion in yearly sales of its Prevnar vaccine. That figure could grow to $6 billion or $7 billion, according to some analysts' estimates, if the U.S. Food and Drug Administration approves a new version of the vaccine for use in children and, after that, in adults 50 and older.
BUSINESS
August 12, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Wyeth late yesterday said the Food and Drug Administration had delayed approval of Prevnar 13, a vaccine that is one of the primary drivers behind the company's anticipated $68 billion merger with Pfizer Inc. Wyeth said the 90-day delay would have no impact on its acquisition by Pfizer and also said it still expects the FDA to approve Prevnar 13. The agency delayed the approval date from Sept. 30 to Dec. 30 after Wyeth submitted new information about how it was measuring and validating the vaccine's physical and chemical properties.
BUSINESS
October 17, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Pfizer Inc.'s acquisition of Wyeth is expected to cut billions from the combined companies' research and development budget, but a senior executive at the new company said it would continue to produce promising new treatments. The companies completed their merger Thursday and began operating as a single company yesterday. Geno Germano, who had been president of Wyeth's U.S. and pharmaceutical business units in Collegeville, will head Pfizer's specialty businesses, which will be based at the Montgomery County facility.
BUSINESS
April 22, 2004 | By Linda Loyd INQUIRER STAFF WRITER
Despite an increase in revenue, Wyeth's first-quarter profit fell 41 percent compared with a year ago, when earnings were boosted by a onetime gain, the company said yesterday. Shares of Wyeth, maker of Centrum vitamins and Advil pain medicine, rose $1.28, or 3.28 percent, to close at $40.28 after the pharmaceutical manufacturer beat some analysts' expectations for first-quarter earnings. "We are obviously very pleased with the first-quarter results despite challenges," chief financial officer Kenneth Martin told investors in a conference call.
BUSINESS
January 9, 2006 | By Linda Loyd INQUIRER STAFF WRITER
In another sign that large drug companies are banking on biotechnology for their future, Wyeth signed product-development deals with three biopharmaceutical firms in the last 2 1/2 weeks. Wyeth said Tuesday that it reached a deal with privately held Trubion Pharmaceuticals Inc. in Seattle to develop and comarket the smaller company's treatments for inflammatory diseases and cancer. Wyeth paid Trubion an initial $40 million, and could pay more than $800 million, excluding royalties and copromotion fees, if certain development milestones were met. Trubion's most advanced product is an experimental drug in mid-stage trials for rheumatoid arthritis.
BUSINESS
July 21, 2009 | By Miriam Hill INQUIRER STAFF WRITER
It took just a few minutes for the vast majority of Wyeth shareholders to say goodbye to the 83-year-old pharmaceutical giant at the company's last annual meeting yesterday. About 98 percent of Wyeth shareholders voted to approve the company's $68 billion acquisition by New York-based Pfizer. Wyeth is based in Madison, N.J., but employs about 5,000 people at operations in Collegeville and Malvern. The deal will solidify Pfizer's position as the top-selling drugmaker in the world and help it compensate for billions of dollars in revenue it likely will lose when its cholesterol fighter Lipitor loses its patent in 2011.
BUSINESS
July 21, 2006 | By Thomas Ginsberg INQUIRER STAFF WRITER
Wyeth, whose best-known products include Advil and Robitussin, said yesterday that biological drugs now account for nearly one-third of its revenue and are growing fastest. "That is surely the growth area of this corporation," Bernard Poussot, president of the Collegeville-based pharmaceutical division of Wyeth, said in announcing the company's second-quarter results. Revenue from Wyeth's vaccine Prevnar, a biological treatment for pneumococcal disease, rose 60 percent in the second quarter over a year earlier, to $518 million from $323.
BUSINESS
January 31, 2007 | By Thomas Ginsberg INQUIRER STAFF WRITER
Here is something you may not hear every day: The drug giant Wyeth said yesterday that it was "surprised" to hear that it is about to face generic competition on its $216 million heart drug Inderal LA. The surprise announcement a day earlier helped beat down Wyeth shares along with news that it had missed Wall Street's profit projections. Wyeth shares on the New York Stock Exchange sank more than 2 percent, or $1.24, to close at $49.36. In its earnings report, Wyeth said strong sales of its antidepressant Effexor and vaccine Prevnar helped raise fourth-quarter profit 17 percent.
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
BUSINESS
January 22, 2013
In the Region   Track expansion to bring crude oil to region   CSX announced a $26 million track capacity expansion on its River Line between Albany, N.Y., and North Jersey, enabling the railroad operator to handle more trains moving crude oil to East Coast refineries. Demand for crude oil in New Jersey and the Philadelphia area "may be as much as five trains per day, or over 400,000 barrels, over the next couple of years," Oscar Munoz, executive vice president and chief operating officer, said in a statement.
NEWS
January 1, 2012 | Associated Press
WASHINGTON - Federal regulators have approved a vaccine for adults 50 and older to prevent pneumococcal disease, including the most common type of pneumonia. Friday's announcement from the Food and Drug Administration that it had approved Pfizer Inc.'s best-selling Prevnar 13 vaccine for such use was widely anticipated. The approval comes a little more than a month after a panel of federal health experts voted overwhelmingly to recommend Prevnar 13 as a safe and effective vaccine to prevent the bacterial infections in adults.
NEWS
November 21, 2011
W. Richey Neuman guides Pfizer Inc.'s vaccines strategy. He works from his office in Collegeville, but talks of burros - laden with coolers to keep vaccines cold - tiptoeing along paths in Nicaragua to deliver Prevnar 13, the latest version of a vaccine given to infants and children before their sixth birthday to ward off potentially fatal bacterial infections that can cause pneumonia. The vaccine brought in $2.82 billion in the first nine months of 2011. Neuman, 52, played mellophone in the Stanford University band, which is famous in the college football world for having gone on the field too early at the end of a 1982 game against Cal, leaving a Cal player to weave through the band for a winning touchdown.
NEWS
November 14, 2011 | By Matthew Perrone, ASSOCIATED PRESS
WASHINGTON - Federal health scientists say Pfizer's best-selling vaccine, Prevnar 13, is at least as effective as rival Merck's at helping prevent sometimes deadly infections in adults. Prevnar 13 is intended to reduce the risk of infection by 13 strains of pneumococcal disease, which causes ear infections, meningitis and pneumonia. Vaccination with Prevnar is recommended for all U.S. infants and young children, because of their vulnerability to infection. But the disease also affects 36,000 older adults per year, killing 5,000 of them, according to the latest figures from the Centers for Disease Control and Prevention.
BUSINESS
February 25, 2010 | By Marie McCullough INQUIRER STAFF WRITER
The Food and Drug Administration yesterday approved a new version of the Prevnar childhood vaccine that will provide greater protection against certain serious bacterial infections. Prevnar 13 stimulates the immune system to fight 13 strains of pneumococci - six more than the original top-selling vaccine, introduced in 2000. These bacteria cause potentially deadly meningitis, bloodstream infections, and pneumonia, as well as ear infections. The approval was a champagne-toast moment for New York-based Pfizer Inc., which last year acquired Prevnar's developer Wyeth.
BUSINESS
November 10, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Pfizer Inc., which bought rival Wyeth last month, said yesterday that it would move "a number of functions" from Wyeth's Collegeville, Montgomery County, location as Pfizer consolidated research and development at five "hub" sites. Separately yesterday, Johnson & Johnson told Pennsylvania state officials that it would lay off 174 people at its Spring House facility as it pushed forward with 8,000 global job cuts the company announced last week. Pfizer would not immediately say how many jobs would be eliminated at Collegeville - Wyeth's long-term pharmaceutical headquarters - where it employs 3,600.
BUSINESS
October 17, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Pfizer Inc.'s acquisition of Wyeth is expected to cut billions from the combined companies' research and development budget, but a senior executive at the new company said it would continue to produce promising new treatments. The companies completed their merger Thursday and began operating as a single company yesterday. Geno Germano, who had been president of Wyeth's U.S. and pharmaceutical business units in Collegeville, will head Pfizer's specialty businesses, which will be based at the Montgomery County facility.
BUSINESS
August 12, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Wyeth late yesterday said the Food and Drug Administration had delayed approval of Prevnar 13, a vaccine that is one of the primary drivers behind the company's anticipated $68 billion merger with Pfizer Inc. Wyeth said the 90-day delay would have no impact on its acquisition by Pfizer and also said it still expects the FDA to approve Prevnar 13. The agency delayed the approval date from Sept. 30 to Dec. 30 after Wyeth submitted new information about how it was measuring and validating the vaccine's physical and chemical properties.
BUSINESS
July 21, 2009 | By Miriam Hill INQUIRER STAFF WRITER
It took just a few minutes for the vast majority of Wyeth shareholders to say goodbye to the 83-year-old pharmaceutical giant at the company's last annual meeting yesterday. About 98 percent of Wyeth shareholders voted to approve the company's $68 billion acquisition by New York-based Pfizer. Wyeth is based in Madison, N.J., but employs about 5,000 people at operations in Collegeville and Malvern. The deal will solidify Pfizer's position as the top-selling drugmaker in the world and help it compensate for billions of dollars in revenue it likely will lose when its cholesterol fighter Lipitor loses its patent in 2011.
BUSINESS
April 19, 2009 | By Miriam Hill INQUIRER STAFF WRITER
They are lethal bacteria. They slink into the human body cloaked in any of 91 versions of fuzzy sugar clouds that act as a coat of armor as they assault the immune system. For drug giant Wyeth, the opportunity to prevent these bacteria, known as pneumococci, from causing meningitis in children already rings up $2.7 billion in yearly sales of its Prevnar vaccine. That figure could grow to $6 billion or $7 billion, according to some analysts' estimates, if the U.S. Food and Drug Administration approves a new version of the vaccine for use in children and, after that, in adults 50 and older.
1 | 2 | Next »
|
|
|
|
|